Nuclear receptors as drug targets for metabolic disease.
about
Bezafibrate administration improves behavioral deficits and tau pathology in P301S miceNuclear Receptor Signaling Atlas: Opening Access to the Biology of Nuclear Receptor Signaling PathwaysMacrophage-independent regulation of reverse cholesterol transport by liver X receptors.Traditional Chinese medicine for lipid metabolism disorders.A screening cascade to identify ERβ ligands.Regulation of inflammatory and lipid metabolism genes by eicosapentaenoic acid-rich oil.Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?Identification of "Multiple Components-Multiple Targets-Multiple Pathways" Associated with Naoxintong Capsule in the Treatment of Heart Diseases Using UPLC/Q-TOF-MS and Network PharmacologyPeroxisome proliferator-activated receptor and vitamin d receptor signaling pathways in cancer cells.Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?Nutraceuticals and functional foods in the management of hyperlipidemia.Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists.Nuclear receptors and drug metabolism for the personalization of cancer therapy.Research Resources for Nuclear Receptor Signaling Pathways.Allyl isothiocyanate (AITC) inhibits pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation and protects against acetaminophen- and amiodarone-induced cytotoxicity.Nuclear receptors in neural stem/progenitor cell homeostasis.Rg1 Attenuates alcoholic hepatic damage through regulating AMP-activated protein kinase and nuclear factor erythroid 2-related factor 2 signal pathways.Apolipoprotein M regulates the orphan nuclear receptor LRH-1 gene expression through binding to its promoter region in HepG2 cells.Hormone and receptor interplay in the regulation of mosquito lipid metabolismExpression and Function of PPARs in Placenta.Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors.Liver X receptors and atherosclerosis: it is not all cholesterol.Fatty acid binding profile of the liver X receptor α.Retracted: Advances in the physiological and pathological implications of cholesterol.Ligand- and structure-based drug design strategies and PPARδ/α selectivity.Regulation of Oligodendrocyte Differentiation and Myelination by Nuclear Receptors: Role in Neurodegenerative Disorders.Lycopene induces retinoic acid receptor transcriptional activation in mice.Selective deletion of PPARβ/δ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression.Flavonoids and saponins extracted from black bean (Phaseolus vulgaris L.) seed coats modulate lipid metabolism and biliary cholesterol secretion in C57BL/6 miceCholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment
P2860
Q28273620-1C0F9D93-B218-4669-AE46-1EF2E417EDFDQ28547687-B09FF08A-5119-4848-AC48-2BA15A545BDEQ30371540-DAB7BE88-4CBD-49E8-AC37-B51D9175E572Q33733077-6B2E30F8-622B-4291-BC39-4C8D423D1CE9Q34564793-03E0CED0-DCBD-4F9F-B412-76AAC630407FQ36520342-E311ECC8-E54A-442C-A528-2C6CBFDB4357Q36619149-B5754A79-863B-40E5-BACB-F39FBBD71D8AQ36795462-BC0ED7FF-4484-4692-B9BC-49BCAB5BEA3EQ38160745-20C8552F-2B9B-45EC-A23B-5A38F5E82B0EQ38166454-1D255F02-36FB-4DE9-90D1-8A6ABD76948BQ38185452-099817B3-F764-424A-B3E7-745769373E85Q38458918-F4AD97F4-E704-4A0D-AE98-ECB9FFA67D8DQ38704025-7080C7BE-12FA-4B6E-8800-F0E560546F5DQ38842436-BE68EC8B-1C35-49BC-BBBA-480EC35B86A7Q38970938-B7A5B321-AB17-45AE-B57F-DBB699A6CAB2Q39389805-1F3BBF83-D461-4FE8-8DA1-9C9FB18A482EQ39733731-C9E11DA3-9F62-4B4A-8EF6-452F7125205FQ40357875-90422677-266D-4543-8EE6-46C196ACCE05Q41677827-C6433793-0D44-4C79-A6BB-6CB697A5FDD9Q41785615-0ECB7716-B645-4F51-B62F-2E24BDCF91AAQ41896519-C39AD3A4-575A-4968-8F1E-6719F4B3F166Q42394480-0062FACB-2C40-4742-8EDD-BDFE97DDB4E8Q43089720-562C27BE-AC67-4C56-BD6D-CAB91EF8FF81Q46069993-40E2833F-5C5E-4A7F-B3BE-8F7834D307BCQ47657576-FA87DD58-C611-43AC-920A-FEE1CA058C33Q48986828-6AABCA74-BA99-4BD6-BB4D-212088682110Q50509859-50DF44AD-E3B5-4875-BF8D-9856121CE895Q52605977-EE1F24F0-B082-4D1C-9D7B-6D3D942B3F93Q57149857-2B8041B2-C6E7-4566-9732-D0AA8A39606FQ58750511-90EE08AA-96CB-4C1A-A0D2-DA98E3F60CFA
P2860
Nuclear receptors as drug targets for metabolic disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Nuclear receptors as drug targets for metabolic disease.
@ast
Nuclear receptors as drug targets for metabolic disease.
@en
type
label
Nuclear receptors as drug targets for metabolic disease.
@ast
Nuclear receptors as drug targets for metabolic disease.
@en
prefLabel
Nuclear receptors as drug targets for metabolic disease.
@ast
Nuclear receptors as drug targets for metabolic disease.
@en
P2860
P1476
Nuclear receptors as drug targets for metabolic disease.
@en
P2093
Ira G Schulman
P2860
P304
P356
10.1016/J.ADDR.2010.07.002
P407
P577
2010-07-22T00:00:00Z